Key facts
- This page summarizes AI ETI LLC's Form 4 filing for Eliem Therapeutics, Inc. (CLYM).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Aug 2021, 16:21.
AI ETI LLC - 12 Aug 2021 Form 4 Insider Report for Eliem Therapeutics, Inc. (CLYM)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CLYM
- Reported as of
- 12 Aug 2021
- Net transaction value
- +$10,000,000
- SEC form
- 4
- Accepted by SEC
- 16 Aug 2021, 16:21:39 UTC
- Prior SEC filing
- 09 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alejandro Moreno for AI ETI LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
AI ETI LLC filed Form 4 for Eliem Therapeutics, Inc. (CLYM) on 16 Aug 2021.
Change
- Previous filing in this sequence was filed on 09 Aug 2021.
- Current net transaction value: +$10,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELYM
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- +4,209,400
- Change %
- Price
- $0.000000
- Shares after
- 4,209,400
- Date
- 12 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F2
ELYM
transaction
Common Stock
Purchase
- Transaction value
- $10,000,000
- Shares
- +800,000
- Change %
- +19%
- Price
- $12.50
- Shares after
- 5,009,400
- Date
- 12 Aug 2021
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELYM
transaction
Derivative
Series A Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -3,568,375
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,568,375
- Exercise price
- Footnotes
- F1, F2
ELYM
transaction
Derivative
Series B Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -641,025
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 641,025
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.
Footnote F2
The securities reported are held directly by AI ETI LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI ETI LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
Footnote F3
Represents securities purchased in the Issuer's initial public offering.